<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857245</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA034086-01, 2011-555</org_study_id>
    <secondary_id>1R01DA034086-01</secondary_id>
    <nct_id>NCT01857245</nct_id>
  </id_info>
  <brief_title>Intensive Models of HCV Care for Injection Drug Users</brief_title>
  <official_title>Intensive Models of HCV Care for Injection Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Upstate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clemson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prisma Health-Upstate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S.&#xD;
      infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response&#xD;
      (SVR) is associated with increased survival. However, IDUs have had poor access to HCV care&#xD;
      and their success in HCV treatment has been limited. With direct-acting antiviral agents, HCV&#xD;
      treatment delivered within large clinical trials leads to SVR or cure in over 70% of&#xD;
      genotype-1 infected patients, compared to 45% with previous therapies. However, SVR rates are&#xD;
      as low as 14% in real-world settings. The majority of patients who fail to achieve SVR will&#xD;
      develop drug resistance, but the optimal adherence level to minimize resistance is unknown.&#xD;
      If HCV treatment continues to be delivered within current models of care, most IDUs will not&#xD;
      only fail treatment and develop resistance, but may transmit resistant viruses to others. We&#xD;
      have previously developed a multidisciplinary model of HCV care which integrates on-site&#xD;
      primary care, substance abuse treatment, psychiatric care, and HCV-related care within opiate&#xD;
      agonist treatment clinics. To maximize treatment outcomes, we piloted two models of intensive&#xD;
      HCV-related care: directly observed therapy (DOT), and concurrent group therapy (CGT). In our&#xD;
      DOT model, pegylated interferon is administered once weekly, if applicable, and one daily&#xD;
      dose of oral medication is administered at the methadone window. In our CGT model, patients&#xD;
      initiate HCV treatment within a once weekly treatment group which provides powerful social&#xD;
      support to mitigate fears of side effects, promote efficient education, and deliver weekly&#xD;
      injections, if applicable. It is unknown whether either model is better or more&#xD;
      cost-effective than standard on-site care.&#xD;
&#xD;
      PREVAIL 1: In the proposed study, 150 IDUs with chronic HCV (genotype 1) will be recruited&#xD;
      from methadone clinics and randomized to one of three models of care: DOT; concurrent group&#xD;
      treatment; or standard on-site care. Our specific aims are: 1) To determine whether either of&#xD;
      two intensive on-site HCV treatment models (DOT or concurrent group treatment) is more&#xD;
      efficacious than standard on-site treatment for enhancing adherence and SVR, and decreasing&#xD;
      drug resistance; (2) To determine the incidence and factors associated with the development&#xD;
      of drug resistance in IDUs; (3) To perform cost and cost-effectiveness analyses of each&#xD;
      model; (4) To examine the impact of HIV coinfection on adherence and virologic outcomes among&#xD;
      HCV-infected IDUs.&#xD;
&#xD;
      PREVAIL 2: In the proposed study, 60 IDUs with chronic HCV (genotypes 1 2, 3 and 4) will be&#xD;
      recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will&#xD;
      be offered the choice of model of care (either standard on-site, DOT, or concurrent group&#xD;
      treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of&#xD;
      opiate agonist treatment patients initiating treatment with sofosbuvir-based regimens and (2)&#xD;
      to determine adherence rates over time in drug users (genotype 3 and genotype 1 /&#xD;
      IFN-ineligible) initiating a 24 week IFN-free regimen.&#xD;
&#xD;
      PREVAIL 3: In the proposed study, 60 IDUs with chronic HCV (genotype 1 and 4) will be&#xD;
      recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will&#xD;
      be offered the choice of model of care (either standard on-site, DOT, or concurrent group&#xD;
      treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of&#xD;
      opiate agonist treatment patients initiating treatment with oral DAA combination of&#xD;
      sofosbuvir and simeprevir or fixed dose of sofosbuvir and ledipasvir and (2) to determine&#xD;
      adherence rates over time in drug users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PREVAIL 1: In the proposed study, 150 IDUs with chronic HCV (genotype 1) will be recruited&#xD;
      from methadone clinics and randomized to one of three models of care: DOT; concurrent group&#xD;
      treatment; or standard on-site care. Our specific aims are: 1) To determine whether either of&#xD;
      two intensive on-site HCV treatment models (DOT or concurrent group treatment) is more&#xD;
      efficacious than standard on-site treatment for enhancing adherence and SVR, and decreasing&#xD;
      drug resistance; (2) To determine the incidence and factors associated with the development&#xD;
      of drug resistance in IDUs; (3) To perform cost and cost-effectiveness analyses of each&#xD;
      model; (4) To examine the impact of HIV coinfection on adherence and virologic outcomes among&#xD;
      HCV-infected IDUs.&#xD;
&#xD;
      PREVAIL 2: In the proposed study, 60 IDUs with chronic HCV (genotypes 1 2, 3 and 4) will be&#xD;
      recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will&#xD;
      be offered the choice of model of care (either standard on-site, DOT, or concurrent group&#xD;
      treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of&#xD;
      opiate agonist treatment patients initiating treatment with sofosbuvir-based regimens and (2)&#xD;
      to determine adherence rates over time in drug users (genotype 3 and genotype 1 /&#xD;
      IFN-ineligible) initiating a 24 week IFN-free regimen.&#xD;
&#xD;
      PREVAIL 3: In the proposed study, 60 IDUs with chronic HCV (genotype 1 and 4) will be&#xD;
      recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will&#xD;
      be offered the choice of model of care (either standard on-site, DOT, or concurrent group&#xD;
      treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of&#xD;
      opiate agonist treatment patients initiating treatment with oral DAA combination of&#xD;
      sofosbuvir and simeprevir or fixed dose of sofosbuvir and ledipasvir and (2) to determine&#xD;
      adherence rates over time in drug users.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electronically monitored medication adherence</measure>
    <time_frame>12-24 weeks</time_frame>
    <description>Hepatitis C medication adherence will be measured using electronic blister pack monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis C viral load.</measure>
    <time_frame>12 weeks after treatment completion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hepatitis C resistance</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Modified Directly Observed Therapy (mDOT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent Group Treatment (CGT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive Models (mDOT and CGT) of HCV Care</intervention_name>
    <description>Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.</description>
    <arm_group_label>Concurrent Group Treatment (CGT)</arm_group_label>
    <arm_group_label>Modified Directly Observed Therapy (mDOT)</arm_group_label>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both&#xD;
&#xD;
        PREVAIL 1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-infected, Genotype-1&#xD;
&#xD;
          -  Treatment naïve or treatment experienced patients&#xD;
&#xD;
          -  Willing to receive HCV treatment on-site&#xD;
&#xD;
          -  Initiating treatment with direct-acting antiviral agents (DAA) with or without&#xD;
             ribavirin +/- pegylated interferon alfa-2a&#xD;
&#xD;
          -  Receiving methadone or buprenorphine in clinic at least one time per week&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Psychiatrically stable&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Currently enrolled in a methadone or buprenorphine treatment program in the designated&#xD;
             clinics in the Bronx (Melrose, Port Morris, Waters Place)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity (allergy) to interferon, ribavirin or DAA&#xD;
&#xD;
          -  Psychiatrically unstable&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
        PREVAIL 2:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-infected, Genotype-1, , 2, 3, or 4&#xD;
&#xD;
          -  Willing to receive HCV treatment on-site at an opiate agonist treatment program.&#xD;
&#xD;
          -  Initiating treatment with sofosbuvir and ribavirin +/- pegylated interferon alfa-2a&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Currently a patient in one of the designated clinics in the Bronx (Melrose, Port&#xD;
             Morris, Waters Place)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity (allergy) to interferon, ribavirin or sofosbuvir&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
        PREVAIL 3:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-infected, Genotype-1 or 4&#xD;
&#xD;
          -  Willing to receive HCV treatment on-site at an opiate agonist treatment program.&#xD;
&#xD;
          -  Initiating treatment with oral DAA combination of sofosbuvir and simeprevir or fixed&#xD;
             dose of sofosbuvir and ledipasvir.&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Currently a patient in one of the designated clinics in the Bronx (Melrose, Port&#xD;
             Morris, Waters Place)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity (allergy) to sofosbuvir, simprevir or ledipasvir.&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
        PREVAIL 4&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV-infected, Genotype-1&#xD;
&#xD;
          -  Treatment naïve or treatment experienced patients&#xD;
&#xD;
          -  Willing to receive HCV treatment on-site&#xD;
&#xD;
          -  Initiating treatment with direct-acting antiviral agents (DAA) with or without&#xD;
             ribavirin +/- pegylated interferon alfa-2a&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Psychiatrically stable&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity (allergy) to interferon, ribavirin or DAA&#xD;
&#xD;
          -  Psychiatrically unstable&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garland Gudger, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prisma Health-Upstate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>Adherence (attribute)</keyword>
  <keyword>Adverse effects</keyword>
  <keyword>Agonist</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>arm</keyword>
  <keyword>base</keyword>
  <keyword>care delivery</keyword>
  <keyword>Caring</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Clinic</keyword>
  <keyword>Clinical Trials</keyword>
  <keyword>Complex</keyword>
  <keyword>Computer Simulation</keyword>
  <keyword>cost</keyword>
  <keyword>cost effective</keyword>
  <keyword>cost effectiveness</keyword>
  <keyword>Data</keyword>
  <keyword>Development</keyword>
  <keyword>Directly Observed Therapy</keyword>
  <keyword>Disease</keyword>
  <keyword>Dose</keyword>
  <keyword>Drug resistance</keyword>
  <keyword>drug resistant virus</keyword>
  <keyword>Educational aspects</keyword>
  <keyword>Epidemic</keyword>
  <keyword>experience</keyword>
  <keyword>Frequencies (time pattern)</keyword>
  <keyword>Fright</keyword>
  <keyword>Genotype</keyword>
  <keyword>Group Therapy</keyword>
  <keyword>Health Care Costs</keyword>
  <keyword>Health Personnel</keyword>
  <keyword>Healthcare Systems</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C Prevalence</keyword>
  <keyword>Hepatitis C Transmission</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HIV</keyword>
  <keyword>Homelessness</keyword>
  <keyword>improved</keyword>
  <keyword>Incidence</keyword>
  <keyword>Infection</keyword>
  <keyword>Injecting drug user</keyword>
  <keyword>Injection of therapeutic agent</keyword>
  <keyword>Intensive Care</keyword>
  <keyword>Interferons</keyword>
  <keyword>Intervention</keyword>
  <keyword>Knowledge</keyword>
  <keyword>Life</keyword>
  <keyword>Liver diseases</keyword>
  <keyword>Liver Failure</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>Living Costs</keyword>
  <keyword>Mental disorders</keyword>
  <keyword>Methadone</keyword>
  <keyword>methadone clinic/center</keyword>
  <keyword>Modeling</keyword>
  <keyword>Mortality Vital Statistics</keyword>
  <keyword>Motivation</keyword>
  <keyword>multidisciplinary</keyword>
  <keyword>Opiates</keyword>
  <keyword>Oral</keyword>
  <keyword>Outcome</keyword>
  <keyword>Patients</keyword>
  <keyword>Persons</keyword>
  <keyword>Pharmaceutical Preparations</keyword>
  <keyword>Physicians</keyword>
  <keyword>pill (pharmacologic)</keyword>
  <keyword>Play</keyword>
  <keyword>Poverty</keyword>
  <keyword>Primary Health Care</keyword>
  <keyword>programs</keyword>
  <keyword>Psychiatric therapeutic procedure</keyword>
  <keyword>psychosocial</keyword>
  <keyword>Publishing</keyword>
  <keyword>Quality-Adjusted Life Years</keyword>
  <keyword>Randomized</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>randomized trial</keyword>
  <keyword>Recruitment Activity</keyword>
  <keyword>Regimen</keyword>
  <keyword>Resistance</keyword>
  <keyword>Resistance development</keyword>
  <keyword>response</keyword>
  <keyword>Risk</keyword>
  <keyword>risk perception</keyword>
  <keyword>Role</keyword>
  <keyword>Site</keyword>
  <keyword>skills</keyword>
  <keyword>Social support</keyword>
  <keyword>standard care</keyword>
  <keyword>substance abuse treatment</keyword>
  <keyword>success</keyword>
  <keyword>Time</keyword>
  <keyword>Treatment outcome</keyword>
  <keyword>Treatment Protocols</keyword>
  <keyword>treatment site</keyword>
  <keyword>Trust</keyword>
  <keyword>United States</keyword>
  <keyword>Viral</keyword>
  <keyword>Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

